STOCK TITAN

Recursion Pharmaceuticals Inc - RXRX STOCK NEWS

Welcome to our dedicated news page for Recursion Pharmaceuticals (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Recursion Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Recursion Pharmaceuticals's position in the market.

Rhea-AI Summary
RXRX: Recursion reported business updates and financial results for Q2 2023, including a partnership with NVIDIA, clinical study guidance, acquisitions, and progress in drug discovery. Key points include a $50 million investment from NVIDIA, Phase 2 clinical trial readouts expected in 2024 and 2025, and favorable ESG Risk Rating from Morningstar Sustainalytics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
-
Rhea-AI Summary
Recursion (NASDAQ: RXRX) announces participation in KeyBanc Technology Leadership Forum, showcasing its innovative approach to drug discovery and biology decoding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
conferences
-
Rhea-AI Summary
Recursion launches Valence Labs, a machine learning research center focused on developing cutting-edge methods and models for drug discovery. $1 million will be invested in academic-oriented initiatives to support talent development in machine learning research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
none
Rhea-AI Summary
Recursion announced a $50 million investment by NVIDIA to accelerate the development of AI foundation models for biology and chemistry. The collaboration aims to optimize and distribute these models to biotech companies using NVIDIA cloud services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
78.17%
Tags
AI
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
Rhea-AI Summary
Recursion announces acquisition of Cyclica and Valence, enhancing its capabilities in AI-enabled drug discovery. The acquisitions add industry-leading capabilities in digital chemistry, machine learning, and artificial intelligence, enabling Recursion to deploy a comprehensive drug discovery solution. The acquisitions are expected to be completed in Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
Recursion Pharmaceuticals Inc

Nasdaq:RXRX

RXRX Rankings

RXRX Stock Data

1.97B
188.28M
5.65%
92.43%
16.95%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Salt Lake City

About RXRX

recursion pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics. our platform has resulted in the massive parallelization of drug discovery. we have deployed this platform in pursuit of drugs for the treatment of rare genetic diseases. we partner or out-license these leads to major pharmaceutical companies early in development. our horizontal business model focused on discovery accelerates our impact and reduces our costs by avoiding slow and costly in-house development, and allows us to spread risk across many new therapeutic opportunities.